Dose-Response Reduction in Risk of Nasopharyngeal Carcinoma From Smoking Cessation: A Multicenter Case-Control Study in Hong Kong, China

Lijun Wang1†, Zhi-Ming Mai1,2,3†, Roger Kai-Cheong Ngan2,4, Wai-Tong Ng2,5, Jia-Huang Lin1,2,6, Dora Lai-Wan Kwong2,7, Shing-Chun Chiang1,2, Kam-Tong Yuen2,8, Alice Wan-Ying Ng2,9, Dennis Kai-Ming Ip1,2, Yap-Hang Chan2,10, Anne Wing-Mui Lee2,7, Maria Li Lung2,7, Sai Yin Ho1‡ and Tai-Hing Lam1,2‡

1 School of Public Health, University of Hong Kong, Hong Kong, China, 2 Centre for Nasopharyngeal Carcinoma Research (CNPCR), Research Grants Council Area of Excellence Scheme, the University of Hong Kong, Hong Kong, China, 3 Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States, 4 Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China, 5 Department of Clinical Oncology, the University of Hong Kong, Hong Kong, China, 6 Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China, 7 Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China, 8 Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China, 9 Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China, 10 Department of Medicine, Princess Margaret Hospital, Hong Kong, China

Background: Cigarette smoking is associated with nasopharyngeal cancer (NPC) risk. Whether quitting reduces the risk is unclear. We investigated the associations of NPC with duration of and age at quitting in an endemic region.

Methods: We investigated the associations between NPC and quitting in a multicenter case-control study in Hong Kong with 676 newly diagnosed NPC cases and 1,285 hospital controls between 2014 and 2017, using a computer-assisted self-administered questionnaire. Multivariable unconditional logistic regression yielded adjusted odds ratios (AORs) of NPC by quitting status, duration and age of quitting, combinations of duration and age of quitting, and quitting to smoking duration ratio, compared with current smoking.

Results: Quitting (AOR: 0.72; 95% CI: 0.53–0.98) and never smoking (0.73, 0.56–0.95) were associated with lower NPC risk. NPC risk decreased with (i) longer quitting duration (p < 0.01), reaching significance after 11–20 (0.62, 0.39–0.99) and 21+ years (0.54, 0.31–0.92) of quitting; (ii) younger quitting age (p = 0.01), reaching significance for quitting at <25 years (0.49, 0.24–0.97); and (iii) higher quitting to smoking duration ratio (p < 0.01), reaching significance when the ratio reached 1 (0.60, 0.39–0.93). Quitting younger (age <25) appeared to confer larger reductions (49% for ≤10 years of quitting, 50% for
11+ years) in NPC risk than quitting at older ages (25+) regardless of quitting duration (16% for ≤10 years, 39% for 11+ years).

**Conclusions:** We have shown longer duration and younger age of quitting were associated with lower NPC risk, with dose-response relations. Our findings support including smoking as a cause of NPC. Stronger tobacco control measures and quitting services are needed to prevent NPC.

**Keywords:** nasopharyngeal carcinoma, cigarette smoking, smoking cessation, case-control study, dose-response relation

**INTRODUCTION**

Despite its similar cellular or tissue lineage, nasopharyngeal carcinoma (NPC) shows a unique epidemiologic pattern among head and neck cancers. Nonkeratinizing undifferentiated NPC (World Health Organization [WHO] type III) is the predominant histology subtype in East and Southeast Asia, where 71% of NPC cases worldwide occurred, while squamous cell carcinoma and keratinizing undifferentiated carcinoma (WHO type I and II) are predominant in nonendemic regions (1–3). The incidence of NPC also peaks at an earlier age in endemic (45–54 years) than nonendemic (65–74 years) regions (4, 5).

Multiple factors could contribute to the development of NPC, such as Epstein-Barr virus (EBV) infection, host genetics, family history, and occupational exposure to dusts and formaldehyde (1, 6). Asian studies in endemic regions also reported the associations with early life consumption of salted fish (7–9). In 2004 and 2012, the International Agency for Research on Cancer reported that cigarette smoking increases NPC risk in both endemic and nonendemic regions (10, 11), while the Health Consequences of Smoking Report by the US Surgeon General in 2014 only concluded on the carcinogenicity for oropharynx but not for nasopharynx due to insufficient evidence (12). After that, further evidence has emerged (1, 13–16) and a meta-analysis showed that every 10 more pack-years of smoking was associated with 15% higher risk of NPC (17). Our recent individual data meta-analysis of cohort studies in endemic regions has also provided strong evidence for a causal relation between smoking and NPC (18). In contrast, the relation between quitting smoking and NPC remains unclear, and the latest 2020 report of the US Surgeon General on smoking cessation has not stated that quitting reduced the risk of NPC (19). Studies that directly compared NPC risks between former and current smoking were few (13, 20, 21), and the adjusted odds ratio (AOR) in quitters (vs. never smokers) appeared to be even higher than that in current smokers (vs. never smokers) in some studies (22, 23).

A case-control study in the USA, a nonendemic region, reported that compared with current smokers, the risks of squamous cell NPC were lower in 32 quitters who had stopped smoking for less than 5 years (AOR: 0.1; 95% confidence interval (CI): 0.0–0.6), 5–14 years (0.2, 0.1–0.7), and 15+ years (0.2, 0.0–0.8) (20). Although the p for trend was significant (p for trend = 0.003), the AORs did not support a dose-response relation. Four case-control studies have reported the associations between duration of quitting and NPC in endemic regions. One, including 681 NPC cases and 1,078 controls in Thailand, showed a lower NPC risk in quitters who had stopped smoking for >5 years (AOR: 0.65; 95% CI: 0.45–0.96) compared with current smokers, with WHO type III NPC accounting for 68.4% of all cases (21). Another case-control study in Queen Elizabeth Hospital of Hong Kong showed a suggestive lower risk of NPC in quitters who had stopped smoking for 10+ years (0.79, 0.43–1.45), but the study had a small sample size of 73 former smokers among 352 cases (93.2% were WHO type III) (13). Another large case-control study (1,857 NPC cases and 1,907 community controls) in Guangdong and Guangxi, southern China showed that compared with never smokers, NPC risk was lower for short-term quitters (quitting for ≤9 years; AOR: 0.54; 95% CI: 0.39–0.75) but higher for long-term quitters (≥10 years; 1.44, 1.04–2.00) (15). The latest case-control study in Taiwan reported that, compared with never smoking, quitting for ≤5 years was associated with a higher NPC risk (1.54, 1.04–2.29), and quitting for ≥6 years showed no association (1.02, 0.67–1.56 for 6–10 years; 1.25, 0.93–1.69 for >10 years) (16). We have found no reports on NPC risk by age at quitting and smoking duration as of July 2021.

In Hong Kong with one of the highest NPC incidence rates in the world and over 90% cases being nonkeratinizing NPC, we investigated the associations between quitting smoking and NPC risk, using data from the Hong Kong Area of Excellence NPC (HKAoENPC) study with detailed information on quitting and potential confounders.

**METHODS**

**Study Subjects**

The HKAoENPC study is a multicenter case-control study with fieldwork conducted between March 2014 and September 2017 in five major regional hospitals (Queen Mary Hospital, Pamela Youde Nethersole Eastern Hospital, Queen Elizabeth Hospital, Princess Margaret Hospital, and Tuen Mun Hospital) that treated up to 75% of all new NPC cases in Hong Kong. Details of the methods have been reported (24, 25).

Briefly, the cases were primary NPC patients diagnosed with histological and/or radiological evidence within 2 months. The
controls were 1,502 frequency-matched (by sex and 5-year age group) patients or referrals with a new health complaint in the past 12 months in specialist outpatient clinics or new inpatients admitted in the past 3 months in the same hospitals. Those with a history of NPC, dementia, or suspected NPC symptoms such as recent unilateral facial nerve palsy, tinnitus, unilateral hearing loss, and epistaxis were excluded. Following the AsiaLymph guideline of the US National Cancer Institute, we specified that no more than 15% of controls would have the same disease. Controls in specific conditions were further excluded based on known or suspected risk factors of NPC, including immunological, infectious, and/or inflammatory etiology. In the present analysis, we excluded 297 (12.8%) subjects aged over 65 to reduce reverse causality, as smoking cessation in older people was usually due to illness (the “sick quitter” effect) (26, 27). Another 59 (2.5%) subjects were excluded due to missing information on smoking. In total, 1,961 (676 NPC cases and 1,285 hospital controls) were included.

The Institutional Review Board of the HKU/Hospital Authority HK West Cluster (UW 11-192), the HK East Cluster Research Ethics Committee (HKEC-2012-043), the Research Ethics Committee of the Hospital Authority Kowloon Central/Kowloon East (KC/KE-13-0115/ER-2), the Research Ethics Committee of the Kowloon West Cluster [KW/EX-13-073(63–11)], and the NTW Cluster Clinical & Research Ethics Committee (NTWC/CREC/1239-13) approved the study. Written informed consent was obtained from all subjects.

Assessment of Smoking, Quitting, and Covariates

We used a computer-assisted, self-administered questionnaire to minimize interviewer bias. Smoking was assessed by “Have you ever smoked (at least 1 cigarette per day for 6 consecutive months)” with options of “never smoking,” “current smoking,” “former smoking,” and “don’t know.” Those who chose “former smoking” answered either “How many years have you quit smoking?” or “At what age did you stop smoking?” Both duration of quitting and age at quitting were assessed based on the answered question. Subjects who chose “current smoking” or “quitting for less than 2 years” were classified as current smokers, and those who had quit for 2 years or longer were classified as former smokers. The duration of quitting (2–4, 4–10, 11–20, and 21+ years) and age at quitting (45+, 35–44, 25–34, and <25 years) were each classified into four groups. We asked “how many cigarettes do you usually smoke per day” in subjects who still smoked and the numbers of cigarettes smoked per day before quitting in those who had quit. The duration of smoking was calculated by subtracting the age at smoking initiation (“At what age did you start smoking?”) from the age at quitting. The duration of quitting was divided by the duration of smoking to calculate the quitting to smoking duration ratio and recoded as <0.5, 0.5–<1, and ≥1. We hypothesized that longer duration of quitting relative to smoking (larger values of quitting to smoking duration ratio) was associated with lower NPC risk. We reinterviewed 140 subjects after around 30 weeks and found high reliability coefficients (0.84–1.00) of smoking and quitting status (25).

Information on sociodemographic characteristics, lifestyle, and putative risk factors of NPC was collected, including sex, age, education, parental education, housing type at the age of 10 years, current household income, alcohol drinking (at least once a week for 6 consecutive months), consumption of salted fish at 6–12 years old (yes/no), family history of cancer (none; non-NPC cancers; NPC), and exposure to occupational hazards (including dust, chemical gas, fumes, acid, or alkali) (yes/no).

Statistical Analysis

Chi-square test was used to assess the differences in background characteristics between cases and controls. To analyze the associations of NPC with smoking status, duration of quitting and age at quitting, odds ratios (ORs) and 95% CIs were calculated using unconditional multivariable logistic regression models, adjusting for potential confounders including sex, age, education, parental highest education, housing type at the age of 10 years, current household income, alcohol drinking, and the number of cigarettes smoked per day. Despite being a strong risk factor for NPC, EBV was not adjusted for as it has been found to mediate the association between smoking and NPC (16, 28, 29). To assess dose-response relation, we tested the linear trends of NPC risk by the duration of quitting, age at quitting, and quitting to smoking duration ratio. Given the high negative correlation between duration of quitting and age at quitting, we assessed NPC risks for different combinations of quitting duration and age at quitting, rather than mutually adjusting for them in regression models.

As sex, consumption of salted fish at age 6–12 years, family history of cancer, and exposure to occupational hazards are putative risk factors of NPC (6–9) and could modify the effect of quitting smoking on NPC, interaction effects were assessed by introducing the interaction (cross-product) terms into regression models. All statistical analyses were conducted using R version 4.0.0 (R Foundation for Statistical Computing Platform). All tests were two-sided with p < 0.05 indicating statistical significance.

RESULTS

Compared with 1,285 controls, the 676 NPC cases had lower education levels (self and parental) and current household income, but higher proportions of family history of NPC, alcohol drinking, and exposure to occupational hazards (all p-values <0.05). No difference was observed for housing type at the age of 10 years, consumption of salted fish at age 6–12, and number of cigarettes smoked per day in ever smokers (Table 1).

Table 2 shows that compared with current smoking, both quitting (AOR: 0.72; 95% CI: 0.53–0.98) and never smoking (0.73, 0.56–0.95) were associated with lower risks of NPC. The ORs of NPC generally decreased with increasing duration of quitting (p for trend: <0.01), reaching statistical significance after quitting for 11–20 (AOR: 0.62; 95% CI: 0.39–0.99) and 21+ years (0.54, 0.31–0.92). NPC risks were lower for quitting at younger
age (p for trend = 0.01), reaching significance at age <25 (0.49, 0.24–0.97) but were not significant for quitting at age 25–34 (0.68, 0.42–1.11), 35–44 (0.72, 0.43–1.23), and 45+ (0.73, 0.44–1.19). The AORs showed dose-response relations for duration of quitting and age at quitting. Similar patterns of associations and trends were observed in men, but the results were unstable in women due to small number of quitters. Table 3 shows that quitting younger at age <25 appeared to confer larger reductions in NPC risk after quitting for both ≤10 years (AOR: 0.51; 95% CI: 0.10–2.55) and 11+ years (0.50, 0.24–1.05) than quitting at age ≤25 after quitting for ≤10 years (0.84, 0.54–1.29) and 11+ years (0.61, 0.40–0.93). Table 4 shows dose-response relation that NPC risk decreased with quitting to smoking duration ratio (p for trend: <0.01), reaching statistical significance when the quitting duration was as long as the smoking duration (ratio ≥1; 0.60, 0.39–0.93). None of the putative risk factors, including sex, consumption of salted fish at age 6–12 years, family history of cancer, and exposure to occupational hazards, showed interaction with quitting status, duration of quitting, or age at quitting in the associations.

**DISCUSSION**

This study showed dose-response reductions in risk of nasopharyngeal carcinoma with younger age at quitting and longer duration of quitting. NPC risk reduction was 29% for 5–10 years of cessation, 38% for 11–20 years, and 46% for 21+ years. NPC risk was halved by quitting smoking before the age of 25 years. These patterns were consistent with those for other types of head and neck cancers (30, 31). We did not find effect modification by the three major putative risk factors of NPC—consumption of salted fish at 6–12 years, family history of cancer, and exposure to occupational hazards—in the associations between quitting smoking and NPC.
TABLE 2 | Associations between quitting smoking and nasopharyngeal carcinoma (cases vs. controls) in subjects aged 18–65 by sex.

| Smoking status | Cases/controls | Sex and age adjusted (95% CI)<sup>b</sup> | Multivariable-adjusted OR (95% CI)<sup>c</sup> | Cases/controls | Sex and age adjusted (95% CI)<sup>b</sup> | Multivariable-adjusted OR (95% CI)<sup>c</sup> | Cases/controls | Sex and age adjusted (95% CI)<sup>b</sup> | Multivariable-adjusted OR (95% CI)<sup>c</sup> |
|----------------|---------------|-----------------------------------------|-----------------------------------------|---------------|-----------------------------------------|-----------------------------------------|---------------|-----------------------------------------|-----------------------------------------|
| **Current**    | 194/257       | 0.67 (0.49, 0.90)**                     | 0.72 (0.53, 0.98)*                      | 176/231       | 0.68 (0.49, 0.99)*                      | 0.74 (0.53, 1.02)                         | 18/26         | 0.50 (0.18, 1.44)                       | 0.54 (0.18, 1.63)                         |
| **Former**     | 108/202       | 0.62 (0.49, 0.78)**                     | 0.73 (0.56, 0.95)*                      | 218/451       | 0.62 (0.48, 0.81)**                     | 0.73 (0.54, 0.99)*                         | 156/375       | 0.58 (0.30, 1.10)                       | 0.71 (0.31, 1.64)                         |
| **Never**      | 374/826       |                                          |                                         |               |                                         |                                         |               |                                         |                                         |
| Duration of quitting (years) |               |                                          |                                         |               |                                         |                                         |               |                                         |                                         |
| 2–4            | 20/26         | 0.97 (0.52, 1.80)                       | 1.02 (0.54, 1.90)                       | 19/23         | 1.02 (0.54, 1.95)                       | 1.08 (0.56, 2.08)                         | 1/3           | – (-)                                  | – (-)                                   |
| 5–10           | 28/55         | 0.65 (0.40, 1.07)                       | 0.71 (0.43, 1.19)                       | 23/47         | 0.61 (0.36, 1.05)                       | 0.67 (0.38, 1.16)                         | 5/8           | 0.90 (0.24, 3.39)                       | 0.76 (0.17, 3.38)                         |
| 11–20          | 33/66         | 0.59 (0.37, 0.94)*                      | 0.62 (0.39, 0.99)*                      | 33/59         | 0.66 (0.41, 1.07)                       | 0.70 (0.43, 1.13)                         | 0/7           | – (-)                                  | – (-)                                   |
| 21+            | 27/55         | 0.51 (0.30, 0.88)*                      | 0.54 (0.31, 0.92)*                      | 26/53         | 0.53 (0.31, 0.89)*                      | 0.55 (0.32, 0.96)*                         | 1/2           | – (-)                                  | – (-)                                   |
| **P for trend** |               | 0.001                                   | <0.01                                   |               | 0.01                                    | 0.01                                    |               |                                         |                                         |
| Age at quitting |               |                                          |                                         |               |                                         |                                         |               |                                         |                                         |
| 45+            | 37/57         | 0.67 (0.41, 1.09)                       | 0.73 (0.44, 1.19)                       | 36/56         | 0.69 (0.42, 1.12)                       | 0.74 (0.45, 1.22)                         | 1/1           | – (-)                                  | – (-)                                   |
| 35–44          | 26/46         | 0.69 (0.41, 1.17)                       | 0.72 (0.43, 1.23)                       | 24/43         | 0.69 (0.40, 1.19)                       | 0.73 (0.42, 1.28)                         | 2/3           | 0.75 (0.10, 5.43)                       | 0.73 (0.07, 7.16)                         |
| 25–34          | 32/63         | 0.65 (0.41, 1.04)                       | 0.68 (0.42, 1.11)                       | 30/53         | 0.71 (0.43, 1.16)                       | 0.76 (0.46, 1.27)                         | 2/10          | 0.31 (0.06, 1.65)                       | 0.23 (0.04, 1.41)                         |
| <25            | 13/36         | 0.48 (0.25, 0.93)*                      | 0.49 (0.24, 0.97)*                      | 11/30         | 0.47 (0.23, 0.97)*                      | 0.49 (0.23, 1.04)                         | 2/6           | 0.51 (0.09, 2.98)                       | 0.51 (0.07, 3.98)                         |
| **P for trend** |               | <0.01                                   | 0.01                                    |               | 0.01                                    | 0.04                                    |               | 0.17                                    | 0.17                                    |

*p < 0.05, **p < 0.01, ***p < 0.001. OR, odds ratio; CI, confidence interval.

ORs were not shown due to insufficient subjects (<2 NPC cases) in the corresponding categories.

No interaction with sex, salted fish consumption, family history of cancer, or exposure to occupational hazards (p-values for interaction ranging from 0.14 to 0.99).

Adjusted for sex and 5-year age group.

Adjusted for sex, 5-year age group, education, parental highest education, housing type at the age of 10 years, current household income, alcohol drinking, and the number of cigarettes smoked per day.

Current smokers included ever smokers who quit for <2 years. Quitting was defined as having stopped smoking for ≥2 years.

*p-values for trends with current smokers as the reference group.
TABLE 3 | Nasopharyngeal carcinoma risk for combinations of quitting duration and age at quitting in subjects aged 18–65.

| Cases/controls | Sex- and age-adjusted OR (95% CI)* | Multivariable-adjusted OR (95% CI)b |
|----------------|-----------------------------------|-------------------------------------|
| Current smoking2 | 194/257 | Ref | Ref |
| Quitting older + shorter duration | 46/73 | 0.78 (0.51, 1.19) | 0.84 (0.54, 1.29) |
| Quitting older + longer duration | 49/93 | 0.58 (0.38, 0.88)* | 0.61 (0.40, 0.93)* |
| Quitting younger + shorter duration | 2/8 | 0.49 (0.10, 2.42) | 0.51 (0.10, 2.55) |
| Quitting younger + longer duration | 11/28 | 0.47 (0.23, 0.98)* | 0.50 (0.24, 1.03) |

*p < 0.05. OR, odds ratio; CI, confidence interval. Notes: Age at quitting was classified as <25 and 25+ years, and duration of quitting was classified as <2 years and ≥2 years.

2Adjusted for sex and 5-year age group.

bAdjusted for sex, 5-year age group, education, parental highest education, housing type at the age of 10 years, current household income, alcohol drinking, and the number of cigarettes smoked per day. No interaction with sex, salted fish consumption, family history of cancer, or exposure to occupational hazards (p-values for interaction ranging from 0.15 to 0.99).

TABLE 4 | Nasopharyngeal carcinoma risk by quitting to smoking duration ratio in subjects aged 18–65.

| Cases/controls | Sex- and age-adjusted OR (95% CI)* | Multivariable-adjusted OR (95% CI)b |
|----------------|-----------------------------------|-------------------------------------|
| Current smoking2 | 194/257 | Ref | Ref |
| Quitting to smoking duration ratio <0.5 | 48/76 | 0.74 (0.49, 1.12) | 0.78 (0.51, 1.19) |
| Quitting to smoking duration ratio 0.5–<1 | 18/36 | 0.62 (0.34, 1.13) | 0.65 (0.35, 1.19) |
| Quitting to smoking duration ratio ≥1 | 41/87 | 0.56 (0.37, 0.86)** | 0.60 (0.39, 0.93)* |
| P for trend | | <0.01 | <0.01 |

*p < 0.05. *p < 0.01. OR, odds ratio; CI, confidence interval.

2Adjusted for sex and 5-year age group.

As with previous studies (14, 44), the associations were mainly observed in men but not in women, probably due to the small numbers of NPC and smokers in women. Our individual data meta-analysis of cohort studies on 334,935 men in endemic regions only observed 48 NPC cases who had quit cigarette smoking, and the risk reduction was nonsignificant (22 cases who quit for <5 years—AOR: 1.22; 95% CI: 0.78–1.90; 26 cases who had quit for ≥5 years: 0.91, 0.60–1.36) (18). The above results suggest that case-control study is probably the most feasible study type for causal inference between quitting smoking and NPC, especially when assessing dose-response relations.

In line with “reversibility” in Bradford Hill criteria for causality, our findings that quitting smoking was associated with reduced NPC risk strengthen the existing relation between smoking and NPC (13–16, 20, 21, 23, 31–41). We found a nonsignificantly lower risk after quitting for 5 to 10 years and significantly lower risks after 11 years. Risk reduction of NPC by age at quitting has not been reported previously. Although NPC risk declined with quitting at younger age, only quitting before 25 years was associated with a significantly reduced risk.

Despite that both age and duration of quitting were associated with NPC risk, smokers should not delay quitting and try to compensate by a longer duration of quitting, because we also found that quitting at young age could be more important than quitting for a long duration. In former smokers who quit younger than 25, NPC risk was halved regardless of quitting duration even for ≤10 years, but in those who quit at or older than 25, risk reduction appeared to be smaller even after quitting for 11+ years (38%). We first used quitting to smoking duration ratio to test the dose-response effects of quitting duration accounting for the effects of smoking duration, which could also be applicable to other health outcomes. The results showed that NPC risk decreased with higher quitting to smoking duration ratio and was reduced by 40% when the ratio was ≥1, i.e., quitting duration reached smoking duration. Quitting young means lower cumulative exposure to tobacco smoke and less harm on health that may take shorter time to reverse (42). This “early quitting protective effect” is plausible because of the young peak age of NPC in endemic regions such as Hong Kong (4, 5). Why such results were observed in Hong Kong but not elsewhere can also be explained by its large decrease in smoking prevalence with more quitters in general and in NPC patients than in China Mainland and other endemic regions (43).
is the most important risk factor for NPC (50) and is associated with elimination of exposure to cigarette smoking itself. EBV reactivation smoking would incur additional benefits apart from eliminating exposure to cigarette smoke itself. EBV reactivation is the most important risk factor for NPC (50) and is associated with smoking. Several large studies in healthy subjects showed that both smoking (28, 51) and cotinine (52) were associated with higher seropositivity for several bio-markers of EBV reactivation and subsequently with higher risk of NPC (16, 29). Further studies are needed to confirm whether quitting smoking can reduce EBV reactivation, and in turn, prevent the development of NPC.

Major strengths of the present study were the large sample size and detailed information on smoking and quitting, including duration of quitting, age at quitting, and smoking duration and intensity. Moreover, Hong Kong has entered the late stage of the smoking epidemic with a higher proportion of former smokers than other endemic areas in southern China. This, together with its high NPC incidence, has made Hong Kong an opportunistic place for our study.

Our study had several limitations. First, the retrospective study design was subject to recall errors, especially for childhood exposures, although we have shown good reliability of the self-reported lifetime experiences by our previous test-retest study (25). Second, as a case-control study, recall bias, Berkson’s bias, and residual confounding could affect the associations. NPC cases could be more likely to report smoking and quitting than healthy controls who also smoked, but such recall bias would be reduced by using hospital controls who also have diseases. Hospital controls would also improve the similarity of unmeasured characteristics between case and control groups. In addition, indirect Berkson’s bias (overestimated associations because another disease is associated with the exposure under study) would be attenuated, because we used incident cases rather than prevalent cases (53). Third, insufficient women were included largely due to the low smoking and quitting rates, and further studies in women are needed to verify the associations. Ideally, the negative association between quitting and NPC should be confirmed by prospective cohort studies. However, it would be difficult to set up a large cohort and follow them for decades to obtain enough NPC cases who have quit smoking, especially for testing the effects of quitting at young age, quitting for long duration, and dose-response relations. Hence, large case-control studies are probably the most feasible study type for causal inference. Collaborative individual participant data meta-analysis of case-control and cohort studies from all endemic regions are warranted.

CONCLUSIONS

We have shown that longer duration of quitting and younger age at quitting were associated with lower NPC risk with dose-response relations in an NPC endemic region. Our findings support that NPC should be included as a cancer that can be caused by smoking. More stringent tobacco control measures and more effective smoking cessation campaigns and services are needed to prevent NPC.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board of the HKU/Hospital Authority HK West Cluster (UW 11-192), the HK East Cluster Research Ethics Committee (HKEC-2012-043), the Research Ethics Committee of the Hospital Authority Kowloon Central/Kowloon East (KC/KE-13-0115/ER-2), the Research Ethics Committee of the Kowloon West Cluster [KW/EX-13-073(63-11)], and the NTW Cluster Clinical & Research Ethics Committee (NTWC/CREC/1239-13). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

SH and T-HL had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. LW and Z-MM designed the study, collected data, carried out the initial analyses, drafted the initial manuscript, and reviewed and revised the manuscript. RN, W-TN, J-HL, DK, SCC, K-TY, AN, DI, Y-HC, AL, and ML collected data and reviewed and revised the manuscript. SH and T-HL conceptualized the study, supervised the data collection and analyses, and critically reviewed and revised the manuscript. All authors contributed to the article and approved the submitted version.
FUNDING
This study was funded by the Hong Kong RGC Area of Excellence Scheme (Grant Number AoE/M-06/08), the World Cancer Research Fund UK (WCRF UK), Wereld Kanker Onderzoek Fonds (WCRF NL), as part of the WCRF International Grant Programme (Grant 2011/460), and Sir Robert Kotewall Professorship in Public Health. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or report writing.

ACKNOWLEDGMENTS
The authors thank all the subjects who provided information for this study.

REFERENCES
1. Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal Carcinoma. Lancet (2016) 387(10022):1012–24. doi: 10.1016/S0140-6736(15)00559-0
2. Jia WH, Qin HD. Non-Viral Environmental Risk Factors for Nasopharyngeal Carcinoma: A Systematic Review. Semin Cancer Biol (2012) 22(2):117–26. doi: 10.1016/j.semcancer.2012.01.009
3. Lee AW, Lung ML, Ng WT. Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. London, United Kingdom: Academic Press (2019).
4. Chang ET, Adami HO. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 15(10):1765–77. doi: 10.1158/1055-9966.EPI-06-0353
5. Bray F, Haugen M, Moger TA, Treti S, Aalen OO, Grotmol T. Age-Incidence Curves of Nasopharyngeal Carcinoma Worldwide: Bimodality in Low-Risk Populations and Aetiologic Implications. Cancer Epidemiol Biomarkers Prev (2008) 17(9):2356–65. doi: 10.1158/1055-9966.EPI-08-0461
6. Vaughan TL, Stewart PA, Teschke K, Lynch CF, Swanson GM, Lyon JL, et al. Occupational Exposure to Formaldehyde and Wood Dust and Nasopharyngeal Carcinoma. Occup Environ Med (2000) 57(6):376–84. doi: 10.1136/sem.57.6.376
7. Liu Z, Chang ET, Liu Q, Cai Y, Zhang Z, Chen G, et al. Quantification of Familial Risk of Nasopharyngeal Carcinoma in a High-Incidence Area. Cancer (2017) 123(14):2716–25. doi: 10.1002/cncr.30643
8. Xie SH, Yu IT, Tse LA, Au JSK, Lau JSM. Occupational Risk Factors for Nasopharyngeal Carcinoma in Hong Kong Chinese: A Case-Referent Study. Int Arch Occup Environ Health (2017) 90(5):443–9. doi: 10.1007/s00420-017-1212-4
9. Barrett D, Ploner A, Chang ET, Liu Z, Zhang CX, Liu Q, et al. Past and Recent Salted Fish and Preserved Food Intakes Are Weakly Associated With Nasopharyngeal Carcinoma Risk in Adults in Southern China. J Nutr (2019) 149(9):1596–605. doi: 10.1093/jn/nxz095
10. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco Smoke and Involuntary Smoking. Lyon (FR: International Agency for Research on Cancer (2004). Available at: https://www.ncbi.nlm.nih.gov/books/NBK316407/. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 83.)
11. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal Habits and Indoor Combustions. Lyon (FR: International Agency for Research on Cancer (2012). Available at: https://www.ncbi.nlm.nih.gov/books/NBK304391/. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100E.)
12. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health (2014).
13. Xie S-H, Yu IT-S, Tse LA, Au JSK, Lau JSM. Tobacco Smoking, Family History, and the Risk of Nasopharyngeal Carcinoma: A Case–Referent Study in Hong Kong Chinese. Cancer Causes Control (2015) 26(6):913–21. doi: 10.1007/s10552-015-0572-x
14. Lin JH, Jiang CQ, Ho SY, Zhang WS, Mai ZM, Xu L, et al. Smoking and Nasopharyngeal Carcinoma Mortality: A Cohort Study of 101,823 Adults in Guangzhou, China. BMC Cancer (2015) 15(1):906. doi: 10.1186/s12885-015-1902-9
15. Chang ET, Liu Z, Hildesheim A, Liu Q, Cai Y, Zhang Z, et al. Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. Am J Epidemiol (2017) 185 (12):1272–80. doi: 10.1093/aje/kwx018
16. Hsu WL, Chien YC, Huang YT, Yu KJ, Ko JY, Lin CY, et al. Cigarette Smoking Increases the Risk of Nasopharyngeal Carcinoma Through the Elevated Level of IgA Antibody Against Epstein-Barr Virus Capsid Antigen: A Mediation Analysis. Cancer Med (2020) 9(5):1867–76. doi: 10.1002/cam4.2832
17. Long M, Fu Z, Li P, Nie Z. Cigarette Smoking and the Risk of Nasopharyngeal Carcinoma: A Meta-Analysis of Epidemiological Studies. BMJ Open (2017) 7(10):e016582. doi: 10.1136/bmjopen-2017-016582
18. Lin JH, Wen CP, Jiang CQ, Yuan JM, Chen CJ, Ho SY, et al. Smoking and Nasopharyngeal Cancer: Individual Data Meta-Analysis of Six Prospective Studies on 334 935 Men. Int J Epidemiol (2021) 50(3):975–86. doi: 10.1093/ije/dyab060
19. U.S. Department of Health and Human Services. Smoking Cessation. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health (2020).
20. Vaughan TL, Shapiro JA, Burt RD, Swanson GM, Berwick M, Lynch CF, et al. Nasopharyngeal Cancer in a Low-Risk Population: Defining Risk Factors by Histological Type. Cancer Epidemiol Biomarkers Prev (1996) 5(8):587–93.
21. Fachiroj I, Sangrajrang S, Johansson M, Renard H, Gaborieu V, Chabrier A, et al. Tobacco Consumption and Genetic Susceptibility to Nasopharyngeal Carcinoma (NPC) in Thailand. Cancer Causes Control (2012) 23(12):1995–2002. doi: 10.1007/s10552-012-0077-9
22. Zhu K, Levine RS, Bramm EA, Gnepp DR.baum MK. A Population-Based Case-Control Study of the Relationship Between Cigarette Smoking and Nasopharyngeal Cancer (United States). Cancer Causes Control (1995) 6(6):507–12. doi: 10.1007/BF00054158
23. Zou J, Sun Q, Akiba S, Yuan Y, Zha Y, Tao Z, et al. A Case-Control Study of Nasopharyngeal Carcinoma in the High Background Radiation Areas of Yangjiang, China. J Radiat Res (2000) 41 Suppl(Suppl):53–62. doi: 10.1269/ jrr.41.s53
24. Mai ZM, Lin JH, Ngan RK, Kwong DL, Ng WT, Ng AW, et al. Milk Consumption Across Life Periods in Relation to Lower Risk of Nasopharyngeal Carcinoma: A Multicentre Case-Control Study. Front Oncol (2019) 9:253. doi: 10.3389/fonc.2019.00225
25. Mai ZM, Lin JH, Chiang SC, Ngan RK, Kwong DL, Ng WT, et al. Test-Retest Reliability of a Computer-Assisted Self-Administered Questionnaire on Early Life Exposure in a Nasopharyngeal Carcinoma Case-Control Study. Sci Rep (2018) 8(1):7052. doi: 10.1038/s41598-018-25046-y
26. Marmot M, Brunner E. Alcohol and Cardiovascular Disease: The Status of the U Shaped Curve. BMJ (Clinical Res ed) (1991) 303(6802):565. doi: 10.1136/bmj.303.6802.565
27. GBDO 2016 Alcohol Collaborators. Alcohol Use and Burden for 195 Countries and Territories, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet (2018) 392(10152):1015–35. doi: 10.1016/S0140-6736(18)31310-2
28. He YQ, Xue WQ, Xu FH, Xu YF, Zhang JB, Yu HL, et al. The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations From Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China. EbioMedicine (2018) 30:184–91. doi: 10.1016/j.ebiom.2018.02.019
29. Xu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, et al. An Epidemiological and Molecular Study of the Relationship Between Smoking, Risk of Nasopharyngeal Carcinoma, and Epstein-Barr Virus Activation. J Natl Cancer Inst (2012) 104(18):1396–410. doi: 10.1093/jnci/djs320
30. Marron M, Boffetta P, Zhang ZF, Zaridze D, Wunsch-Filho V, Winn DM, et al. Cessation of Alcohol Drinking, Tobacco Smoking and the Reversal of...
31. Sriamporn S, Phumangkat V, Pisanib P, Yongchajiyudha S, Rungritarangsi V. Environmental Risk Factors for Nasopharyngeal Carcinoma: A Case-Control Study in Northeastern Thailand. *Cancer Epidemiol Biomarkers Prev* (1992) 1 (5):345–8.

32. Yu MC, Garabrant DH, Huang TB, Henderson BE. Occupational and Other Non-Dietary Risk Factors for Nasopharyngeal Carcinoma in Guangzhou, China. *Int J Cancer* (1990) 45(6):1033–9. doi: 10.1002/ijc.2910450609

33. Nam JM, McLaughlin JK, Blot WJ. Cigarette Smoking, Alcohol, and Nasopharyngeal Carcinoma: A Case-Control Study Among U.S. Whites. *J Natl Cancer Inst* (1992) 84(8):619–22. doi: 10.1093/jnci/84.8.619

34. Chelleng PK, Narain K, Das HK, Chetia M, Mahanta J. Risk Factors for Cancer Nasopharynx: A Case-Control Study From Nagaland, India. *Natl Med J Ind 2000* (3):136–8.

35. Feng BJ, Khayatt M, Ben-Ayoub W, Dhahmoul S, Ayad M, Maachi F, et al. Cannabis, Tobacco and Domestic Fumes Intake Are Associated With Nasopharyngeal Carcinoma in North Africa. *Br J Cancer* (2009) 101 (7):1207–12. doi: 10.1038/sj.bjc.6605281

36. Hsu WL, Chen JY, Liu MY, You SL, Hsu MM, et al. Independent Effect of EBV and Cigarette Smoking on Nasopharyngeal Carcinoma: A 20-Year Follow-Up Study on 9,622 Males Without Family History in Taiwan. *Cancer Epidemiol Biomar* (2009) 18(4):1218–26. doi: 10.1186/1055-9965-Epi-08-1175

37. Ji X, Zhang W, Xie C, Wang B, Zhang G, Zhou F. Nasopharyngeal Carcinoma Risk by Histologic Type in Central China: Impact of Smoking, Alcohol and Family History. *Int J Cancer* (2011) 129(3):74–32. doi: 10.1002/ijc.25696

38. Turkoz FP, Celenkoglu G, Dogu GG, Kalender ME, Coskun U, Alkis N, et al. Risk Factors of Nasopharyngeal Carcinoma in Turkey-An Epidemiological Survey of the Anatolian Society of Medical Oncology. *Asian Pac J Cancer Prev* (2011) 12(11):3017–21.

39. Lye M-S, Visuvanathan S, Chong P-P, Yap Y-Y, Lim C-C, Ban E-Z. Homozygous Wildtype of XPD K751Q Polymorphism Is Associated With Increased Risk of Nasopharyngeal Carcinoma in Malaysian Population. *PloS One* (2015) 10(6):e0130530. doi: 10.1371/journal.pone.0130530

40. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Preserved Foods in Relation to Risk of Nasopharyngeal Carcinoma in Shanghai, China. *Int J Cancer* (2000) 85(3):358–63. doi: 10.1002/(sici)1097-0215(20000220)85:3:358<358::aid-ijc11>3.0.co;2-e

41. Friborg JT, Yuan JM, Wang RW, Koh WP, Lee HP, Yu MC. A Prospective Study of Tobacco and Alcohol Use as Risk Factors for Pharyngeal Carcinomas in Singapore Chinese. *Cancer* (2007) 109(6):1183–91. doi: 10.1002/cncr.22501

42. Bhatt SP, Kim YI, Harrington KF, Hokanson JE, Lutz SM, Cho MH, et al. Smoking Duration Alone Provides Stronger Risk Estimates of Chronic Obstructive Pulmonary Disease Than Pack-Years. *Thorax* (2018) 73(5):414–21. doi: 10.1136/thoraxjnl-2017-210722

43. Li HC, Chan SS, Lam TH. Smoking Among Hong Kong Chinese Women: Behavior, Attitudes and Experience. *BMC Public Health* (2015) 15:183. doi: 10.1186/s12889-015-1529-4

44. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Non-Dietary Risk Factors for Nasopharyngeal Carcinoma in Shanghai, China. *Int J Cancer* (2000) 85(3):364–9. doi: 10.1002/(sici)1097-0215(20000220)85:3<364::aid-ijc12>3.0.co;2-c

45. Lau HY, Leung CM, Chan YH, Lee AW, Kwong DL, Lung ML, et al. Secular Trends of Salted Fish Consumption and Nasopharyngeal Carcinoma: A Multi-Jurisdiction Ecological Study in 8 Regions From 3 Continents. *BMC Cancer* (2013) 13:298. doi: 10.1186/1471-2407-13-298

46. Polese J, Franceschi S, Talamini R, Negri E, Barazza L, Montella M, et al. Tobacco Smoking, Alcohol Drinking, and the Risk of Different Histological Types of Nasopharyngeal Cancer in a Low-Risk Population. *Oral Oncol* (2011) 47(6):541–5. doi: 10.1016/j.oraloncology.2011.03.017

47. Thurber KA, Banks E, Joshy G, Soga K, Marmor A, Benton G, et al. Tobacco Smoking and Mortality Among Aboriginal and Torres Strait Islander Adults in Australia. *Int J Epidemiol* (2021) 50(3):942–54. doi: 10.1093/ije/dyaa274

48. Hashim D, Gaughan D, Boffetta P, Lucchini RG. Baseline Serum Beta-Carotene Concentration and Mortality Among Long-Term Asbestos-Exposed Insulators. *Cancer Epidemiol Biomarkers Prev* (2015) 24(3):555–60. doi: 10.1158/1055-9965.EPI-14-0952

49. Hu T, Lin CY, Xie SH, Chen GH, Lu YQ, Ling W, et al. Smoking can Increase Nasopharyngeal Carcinoma Risk by Repeatedly Reactivating Epstein-Barr Virus: An Analysis of a Prospective Study in Southern China. *Cancer Med* (2019) 8(5):2561–71. doi: 10.1002/cam4.2083

50. Young LS, Yap LF, Murray PG. Epstein–Barr Virus: More Than 50 Years Old and Still Providing Surprises. *Nat Rev Cancer* (2016) 16(12):789. doi: 10.1038/nrc.2016.92

51. He YQ, Liao XY, Xue WQ, Xu YF, Xu FH, Li FF, et al. Association Between Environmental Factors and Oral Epstein-Barr Virus DNA Loads: A Multicenter Cross-Sectional Study in China. *J Infect Dis* (2019) 219(3):400–9. doi: 10.1093/infdis/jiy542

52. Yang Q-Y, He Y-Q, Xue W-Q, Zhou T, Liao Y, Zheng M-Q, et al. Association Between Serum Cotinine Level and Serological Markers of Epstein–Barr Virus in Healthy Subjects in South China Where Nasopharyngeal Carcinoma Is Endemic. *Front Oncol* (2019) 9:865. doi: 10.3389/fonc.2019.00865

53. Flanders WD, Boyle CA, Boring JR. Bias Associated With Differential Reporting in Other Forums is permitted, provided the original author(s) and the copyright holder(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.